0001818331-26-000015
SEC filingRevenue grew 40% to $427.5M on 30% exome/genome volume growth; gross margin expanded to 69.7%.
GeneDx Holdings Corp. aims to empower everyone to live their healthiest life through genomics. The company was founded in 2000 by NIH scientists and has amassed one of the world's largest rare disease datasets, GeneDx Infinity, with over 2.5 million tests and more than 1 million exomes/genomes. The company's primary offering is exome and genome sequencing tests (ExomeDx and GenomeDx), which are ranked #1 by expert geneticists and have received FDA Breakthrough Device Designation. Revenue is substantially derived from diagnostic test reports, with approximately 1.5% from outside the United States. The company operates a CLIA-certified laboratory in Gaithersburg, Maryland, accredited by CAP.
The filing does not break out the business into distinct reporting segments. The entire business is described as a single operating segment focused on genomic testing and interpretation services. All revenue is derived from diagnostic test reports, and the company expects to diversify into data information solutions, newborn screening, and interpretation services over time.
Named products and platforms include: ExomeDx, GenomeDx, GeneDx Infinity (the proprietary rare disease dataset), rapid and ultraRapid genome sequencing, genomic newborn screening protocols, and the AI-powered gene ranker Multiscore. The company also has the Fabric Genomics platform, acquired in May 2025, for international expansion. These products are enriched with new genomic technologies like medium and long-read sequencing and multimodal analysis beyond DNA.
The company deploys approximately 120 field-based sales representatives and medical science liaisons. It partners with health systems, manufacturers, commercial and governmental payors, and advocacy groups. Customers include third-party payors, patients, business-to-business clients, and healthcare partners. No specific customer concentration is disclosed in this section (refer to Note 2 for payor concentration). Seasonal demand is observed, with higher revenue in Q4 and lower in Q1 due to annual insurance deductibles.
Principal competitors include Baylor Genetics, Tempus (via Ambry Genetics), Variantyx, and Rady Children's Hospital, as well as other commercial and academic laboratories. The competitive landscape includes specialty and reference labs offering traditional single- and multi-gene tests, as well as new entrants in informatics and integrated genetic tools. Illumina is both a supplier and potential competitor.
The company's strategy focuses on: (1) expanding exome and genome sequencing as the first-tier test over other genetic tests through product enhancements and trust among geneticists; (2) expanding adoption beyond geneticists into general pediatrics, NICU, and prenatal testing; (3) deploying a large sales and medical liaison force; (4) partnering to establish clinical and economic evidence for genomic medicine; (5) opening new markets and geographies, including international expansion via Fabric Genomics; (6) launching a lifelong provider/patient experience with reanalysis; (7) becoming a biopharma solutions provider for rare disease trial recruitment and drug discovery; and (8) creating a network effect uniting patients, researchers, and other stakeholders.
As of the filing, the company employs nearly 1,300 individuals. This includes over 100 MDs and PhDs and 150 genetic counselors. The company emphasizes competitive compensation, equity incentives, and a comprehensive total rewards package to attract and retain talent. Employee engagement surveys are used to inform priorities. The company operates in a competitive industry for highly qualified personnel.
For the year ended December 31, 2025, total revenue rose 40% to $427.5 million from $305.5 million in 2024, driven by a 38% increase in diagnostic test revenue ($416.7 million) and a tripling of other revenue to $10.9 million. The diagnostic test growth was fueled by a 30% increase in exome and genome test volumes (97,271 vs. 74,547) and an 18% rise in average reimbursement rates, partially offset by the phase-out of lower-margin hereditary cancer tests. Gross profit surged 53% to $298.2 million, with gross margin expanding from 63.6% to 69.7%, benefiting from mix shift to whole exome/genome tests and cost-per-test leverage. Operating expenses increased across the board: R&D up 58% to $72.0 million (investment in product development and Fabric Genomics), selling and marketing up 31% to $88.4 million (commercial team expansion), and G&A up 44% to $150.8 million (higher headcount, legal/compliance costs, and amortization, partially offset by an $8.4 million sales-and-use tax refund). Despite higher absolute spending, the loss from operations improved 44% to ($13.1 million), and net loss narrowed 60% to ($21.0 million). Non-operating expenses included a $4.8 million legal settlement and $1.2 million in fair value changes. Operating cash flow turned positive at $33.3 million, compared to ($28.5 million) in 2024.
The company operates primarily through two revenue streams: diagnostic testing and other revenue. Diagnostic test revenue (97% of total) grew 38% to $416.7 million, with exome and genome sequencing revenues rising $126.8 million. This segment is driven by volume growth and improved reimbursement, and management expects continued mix shift toward higher-value tests. Other revenue, including Fabric Genomics' software and interpretation services and biopharma collaborations, grew to $10.9 million from $3.3 million, reflecting acquisition contributions and program expansion. While operating income is not disclosed by segment, the gross margin improvement is largely attributed to the diagnostic segment's mix shift and cost efficiencies.
Management does not provide quantitative guidance in this MD&A. Qualitative expectations include continued absolute dollar increases in R&D, selling and marketing, and G&A as the company invests in commercial expansion and platform innovation, though these expenses are expected to decline as a percentage of revenue over time. The company believes its existing cash and marketable securities of $171.3 million are sufficient for at least twelve months. Key strategic priorities include expanding coverage and reimbursement for exome/genome tests, lowering per-test costs through automation and value engineering, and growing adoption among existing and new customers. The acquisition of Fabric Genomics positions the company to offer AI-enabled genomic interpretation, expanding its total addressable market. Future filings will provide updates on these initiatives.
As of December 31, 2025, GeneDx held $105.0M in cash and cash equivalents and $66.3M in marketable securities, totaling $171.3M in liquid assets. Total debt stood at $52.7M (including $4.5M current portion), primarily consisting of the Perceptive Term Loan Facility ($50M net of issuance costs) and the DECD loan. Shareholders' equity increased to $308.2M from $245.2M, driven by ATM offerings and stock-based compensation. Inventory rose to $14.0M from $10.7M.
Total purchase commitments amounted to $35.7M as of year-end, primarily for software and equipment providers. Approximately $15.1M is due within one year, $15.8M in years 1–3, and $4.9M thereafter. Additionally, lease obligations total $86.4M (undiscounted), with $8.6M due in 2026. The Company also has a contingent consideration liability of $7.0M related to the Fabric Genomics acquisition, with $5.4M classified as short-term.
GeneDx did not repurchase shares or pay dividends during the year. Net debt decreased by $4.0M (from $51.9M to $48.2M) primarily through principal repayments on the DECD loan and finance leases. Capital expenditures were $19.0M, representing 4.4% of total revenue, driven by laboratory equipment and construction in progress. The Company raised $46.7M through ATM offerings, strengthening its cash position.
GeneDx operates as a single reportable segment (GeneDx), with two other operating segments (Fabric Genomics and Legacy Sema4) aggregated as "Other." The GeneDx segment generated $423.1M in revenue (99% of total), up 40% YoY. The Other segment contributed $4.5M, primarily from Fabric Genomics post-acquisition. Adjusted gross profit for GeneDx was $301.0M (71.2% margin), while Other adjusted gross profit was $3.4M. No geographic revenue breakdown was provided.
GeneDx faces significant regulatory risks, particularly potential FDA oversight of laboratory-developed tests (LDTs). Although the 2024 final rule was struck down, future legislation or FDA action could impose premarket review, increasing costs and delaying market entry. Compliance with CLIA, CAP, and state licensure is critical; loss of certification would disrupt operations. HIPAA and state privacy laws impose stringent data protection requirements; breaches could result in fines and reputational damage. The evolving AI regulatory landscape (e.g., EU AI Act) may affect use of AI in diagnostics.
The company relies on a limited number of suppliers, including sole-source providers for sequencing platforms and reagents. Any disruption could halt test processing. Data infrastructure depends on third-party cloud providers; service interruptions could impair operations. Laboratories are concentrated in one location (Gaithersburg, MD), exposing the company to regional disasters.
Intense competition from established players and startups with greater resources may limit market share and pricing power. Rapid technological change requires continuous innovation; failure to keep pace could render products obsolete.
GeneDx has an accumulated deficit of $1.4B and may need additional capital to fund operations and growth. Debt covenants under the Perceptive credit agreement restrict financial flexibility. Revenue is difficult to forecast due to uncertain adoption and reimbursement; fluctuations could impact stock price.
Scaling infrastructure ahead of demand is a key risk; if test volume does not materialize, fixed costs could erode margins. The company depends on highly skilled personnel; competition for talent could hinder growth. Use of AI in interpretation may produce errors, leading to liability or reputational harm.
Protection relies on trade secrets and patents; competitors may develop similar technologies. Patent litigation could be costly and limit commercialization. Open-source software use may trigger license obligations.
Overall, the risk factors are extensive and cover material threats to the business, with reimbursement and regulatory uncertainties being the most impactful.
The document excerpt contains the auditor's report and notes to financial statements but does not include the actual Consolidated Statements of Cash Flows. Therefore, no cash flow metrics such as operating cash flow, capex, or free cash flow can be extracted. The analysis cannot be performed based on the given content.